GlaxoSmithKline has cleared a key hurdle for gaining wider use of its cervical cancer vaccine Cervarix, winning the World Health Organization's approval to offer the jab in developing countries. That official green light is a prerequisite for non-profit groups like GAVI as well as UN agencies that want to buy the vaccine. Cervarix report